SCHEMBL3705241

SCHEMBL3705241

CCCNc1nc(Nc2ccc3c(c2)NC(=O)C3(C)C)nc2ccoc12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 18/20 0.73
LCK P06239 5/20 0.57
JAK2 O60674 4/20 0.57
ABL1 P00519 4/20 0.57
FYN P06241 4/20 0.57
RET P07949 4/20 0.57
MAPK8 P45983 4/20 0.57
TNK2 Q07912 4/20 0.57
MAP4K2 Q12851 4/20 0.57
LTK P29376 3/20 0.57
NTRK2 Q16620 3/20 0.57
KDR P35968 3/20 0.57
ROCK1 Q13464 2/20 0.57
STK16 O75716 2/20 0.57
PTK2 Q05397 2/20 0.57
INSR P06213 2/20 0.57
MST1 P26927 2/20 0.57
AURKA O14965 1/20 0.57
ROCK2 O75116 1/20 0.57
NTRK1 P04629 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3709370 0.88 SYK (0.74) SYKLCKJAK2ABL1FYN
SCHEMBL1709844 0.87 SYK (0.65) SYKLCKJAK2ABL1FYN
SCHEMBL1709886 0.86 SYK (0.68) SYKLCKJAK2ABL1FYN
SCHEMBL3703474 0.83 SYK (0.76) SYKLCKJAK2ABL1FYN
SCHEMBL1709880 0.82 SYK (0.76) SYKLCKJAK2ABL1FYN
SCHEMBL3697246 0.81 SYK (0.71) SYKLCKJAK2ABL1FYN
SCHEMBL3716960 0.81 SYK (0.61) SYKLCKJAK2ABL1FYN
SCHEMBL1709875 0.81 SYK (0.70) SYKLCKJAK2ABL1FYN
SCHEMBL7622611 0.79 SYK (0.55) SYKLCKJAK2ABL1FYN
SCHEMBL1709846 0.77 SYK (0.80) SYKLCKJAK2ABL1FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US claimed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US claimed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 SYK 1176/4885LCK 154/4885JAK2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.